ライフサイエンスコーパス: osteolytic lesion

1 ne among those increased in MM patients with osteolytic lesions.

2 and B-symptoms and was found to have diffuse osteolytic lesions.

3 ssion, radiation or surgery to bone, and new osteolytic lesions.

4 and decrease the progression of established osteolytic lesions.

5 n myeloma cells inhibited the development of osteolytic lesions.

6 mall group of Tax(+) animals presenting with osteolytic lesions.

7 nificantly prevented the formation of severe osteolytic lesions.

8 ant in the resulting suppression of skeletal osteolytic lesions.

9 cell line, C4-2B, induces mixed osteoblastic/osteolytic lesions.

10 te, significantly delayed the progression of osteolytic lesions.

11 alyses to identify molecular determinants of osteolytic lesions.

12 essential for the formation of premetastatic osteolytic lesions.

13 ue associated with progressive periarticular osteolytic lesions.

14 insipidus, bilateral ear discharge, and new osteolytic lesions.

15 with metastatic breast cancer who have known osteolytic lesions.

16 ctures (45 [5%] vs 66 [7%]; p=0.04), and new osteolytic lesions (46 [5%] vs 95 [10%]; p<0.0001).

17 After treatment, 58 osteolytic lesions (80.5%) became [(18)F]FDG negative an

18 CCR1 activation leads to the formation of osteolytic lesions and facilitates tumor growth.

19 toma cells recruited osteoclasts to generate osteolytic lesions and invade the bone matrix.

20 use model of bone metastasis, A77636 reduced osteolytic lesions and prevented mechanical weakening of

21 progeria-like disease phenotypes, including osteolytic lesions and rib fractures, osteoporosis, slow

22 evented splenomegaly, limited development of osteolytic lesions, and concomitantly reduced tumor grow

23 turn a suppressor of osteoclastic activity, osteolytic lesions, and disease burden in a preclinical

24 correlated with markers of bone resorption, osteolytic lesions, and markers of disease activity.

25 Osteolytic lesions are a painful consequence of metastas

26 ue involvement, presence of an abscess or an osteolytic lesion around causative tooth.

27 r survival, a smaller tumor burden, and less osteolytic lesions, as compared with mice bearing contro

28 s that these compounds reduce PTHrP-mediated osteolytic lesions associated with metastatic human brea

29 C4-2B's ability to induce mixed osteoblastic/osteolytic lesions, C4-2B cells were stably transfected

30 , our findings suggest a novel mechanism for osteolytic lesions caused by cancer cells metastasizing

31 treatment completely prevented radiographic osteolytic lesions caused by human MDA-MB-231 breast can

32 tumor primarily metastasizes to bone to form osteolytic lesions, causing severe pain and pathological

33 In cancer-induced osteolytic lesions, cleavage of receptor activator of nu

34 l analysis at weekly intervals revealed that osteolytic lesions developed in the control tibias by 2

35 mechanisms of inhibiting myeloma growth and osteolytic lesion development.

36 r interactions governing the early events of osteolytic lesion formation are currently unclear.

37 Surprisingly, osteolytic lesion formation was greatest in animals lack

38 tumours or systemic delivery of LOX leads to osteolytic lesion formation whereas silencing or inhibit

39 issemination in the bone marrow and enhanced osteolytic lesion formation, irrespective of HIF-1 Conve

40 er cells in the bone marrow and tumor-driven osteolytic lesion formation.

41 tion of LOX activity abrogates tumour-driven osteolytic lesion formation.

42 the progression of soft tissue necrosis and osteolytic lesion formation.

43 Anti-Wnt5a therapy may prevent or reduce osteolytic lesions found in ATL patients and improve the

44 Multiple myeloma is incurable once osteolytic lesions have seeded at skeletal sites, but fa

45 ecrete osteoclastogenic factors that promote osteolytic lesions; however, the identity of these facto

46 s may correlate with a propensity to develop osteolytic lesions in arthritis.

47 pose tissue, micrognathia, osteoporosis, and osteolytic lesions in bone.

48 reast cancer cells can prevent production of osteolytic lesions in bone.

49 lopecia, micrognathia, dental abnormalities, osteolytic lesions in bones, and osteoporosis, which are

50 at MMP-13 is critical for the development of osteolytic lesions in MM and that targeting the MMP-13 p

51 activity of osteoblasts (OBs) contributes to osteolytic lesions in multiple myeloma (MM).

52 very effective in limiting the formation of osteolytic lesions in PC-3 implanted tibias by inhibitin

53 Osteolytic lesions in the ribs led to spontaneous bone f

54 on of DKK1 by MM cells likely contributes to osteolytic lesions in this disease by inhibiting Wnt sig

55 n several human cancer cell lines that cause osteolytic lesions in vivo and produce PTHrP (MDA-MB-231

56 ort that human neuroblastoma cells that form osteolytic lesions in vivo do not produce osteoclast-act

57 tumor cells abolishes their ability to form osteolytic lesions in vivo.

58 n osteoblastic reaction in vitro and induced osteolytic lesions in vivo.

59 bone scans have sensitivity limitations for osteolytic lesions manifested in MM.

60 geting osteoclasts, which are upregulated in osteolytic lesions, may facilitate earlier follow-up in

61 es that produce osteoblastic (MDA PCa 2b) or osteolytic lesions (PC-3).

62 veloped hypercalcemia and significantly more osteolytic lesions than mice bearing CHO/EV tumors, with

63 Infection of the dental pulp leads to an osteolytic lesion that results from a polymicrobial infe

64 a cells in the bone marrow induces localized osteolytic lesions that rarely heal due to increased bon

65 ved to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria

66 Total area of osteolytic lesions was significantly lower in mice treat

67 ith established bone metastases, the size of osteolytic lesions was significantly reduced after 4 wee

68 acquired immune response could contribute to osteolytic lesions, we injected the periodontal pathogen

69 bone marrow plasma from femurs affected with osteolytic lesions were increased 2.5-fold over correspo

70 Microscopic osteolytic lesions were observed adjacent to plasma cell

71 osteolysis in mice receiving control cells, osteolytic lesions were significantly reduced following

72 Osteolytic lesions were successfully quantified using sm

73 The osteolytic lesions, which develop usually in the long bo

74 metastasis produced detectable, progressive osteolytic lesions within 3 weeks of intracardiac inject

75 those cells with increased IGF-IR form both osteolytic lesions within the tibiae and secondary tumor

76 frequently metastasize to bone, resulting in osteolytic lesions, yet the underlying mechanisms are po